Show simple item record

dc.contributor.authorWorld Health Assembly, 47
dc.coverage.spatialGenevaEN
dc.date.accessioned2015-06-24T17:44:17Z
dc.date.available2015-06-24T17:44:17Z
dc.date.issued1994
dc.identifier.govdocA47/A/Conf.Paper No.2
dc.identifier.govdocA47/A/Conf.Paper No.2 Rev.1
dc.identifier.govdocA47/A/Conf.Paper No.2 Rev.2
dc.identifier.urihttp://www.who.int/iris/handle/10665/177057
dc.description(‎Agenda item 19)‎EN
dc.language.isoenEN
dc.publisherWorld Health OrganizationEN
dc.subjectPharmaceutical productsEN
dc.subject.meshPharmaceutical PreparationsEN
dc.subject.meshDrug IndustryEN
dc.subject.meshMarketingEN
dc.subject.meshEthics, PharmacyEN
dc.subject.meshHealth PlanningEN
dc.subject.meshHealth PolicyEN
dc.subject.meshWorld Health OrganizationEN
dc.titleWHO ethical criteria for medicinal drug promotion: draft resolution proposed by the delegations of Australia, Belgium, Botswana, Cameroon, Canada, Chile, Denmark, Finland, Ghana, Guatemala, Iceland, Kenya, Lesotho,Lithuania, Mexico, New Zealand, Niger, Norway, Spain, Sweden, Switzerland, Thailand, United Kingdom of Great Britain and Northern Ireland, United Republic of Tanzania and United States of AmericaEN
dc.typeGoverning body documentsEN
dc.subject.meshqualifierethicsEN


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record